Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management
Abstract
:1. Introduction
2. Methods
3. Epidemiology of BMs in GEP- and BP-NENs
4. Molecular Pathways of BM Development
5. Clinical Presentation of BMs and Skeletal-Related Events
5.1. Pain
5.2. Pathological Fractures
5.3. Spinal Cord Compression
5.4. Hypercalcemia
6. Diagnosis of BMs
6.1. Imaging Procedures
6.2. Biomarkers
7. Impact of BMs on Prognosis
8. Therapy of BMs
9. Impact of BMs on NEN Treatment
10. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Faggiano, A.; Ferolla, P.; Grimaldi, F.; Campana, D.; Manzoni, M.; Davi, M.V.; Bianchi, A.; Valcavi, R.; Papini, E.; Giuffrida, D.; et al. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: The NET management study. J. Endocrinol. Invest. 2012, 35, 817–823. [Google Scholar] [CrossRef] [PubMed]
- Boyar Cetinkaya, R.; Aagnes, B.; Myklebust, T.A.; Thiis-Evensen, E. Survival in neuroendocrine neoplasms; A report from a large Norwegian population-based study. Int. J. Cancer 2018, 142, 1139–1147. [Google Scholar] [CrossRef] [PubMed]
- Dasari, A.; Shen, C.; Halperin, D.; Zhao, B.; Zhou, S.; Xu, Y.; Shih, T.; Yao, J.C. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncol. 2017, 3, 1335–1342. [Google Scholar] [CrossRef] [PubMed]
- Hallet, J.; Law, C.H.; Cukier, M.; Saskin, R.; Liu, N.; Singh, S. Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 2015, 121, 589–597. [Google Scholar] [CrossRef] [PubMed]
- Barrea, L.; Altieri, B.; Muscogiuri, G.; Laudisio, D.; Annunziata, G.; Colao, A.; Faggiano, A.; Savastano, S. Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness. Nutrients 2018, 10, 1854. [Google Scholar] [CrossRef] [PubMed]
- Kos-Kudla, B.; O’Toole, D.; Falconi, M.; Gross, D.; Kloppel, G.; Sundin, A.; Ramage, J.; Oberg, K.; Wiedenmann, B.; Komminoth, P.; et al. ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. Neuroendocrinology 2010, 91, 341–350. [Google Scholar] [CrossRef] [PubMed]
- Garcia-Carbonero, R.; Capdevila, J.; Crespo-Herrero, G.; Diaz-Perez, J.A.; Martinez Del Prado, M.P.; Alonso Orduna, V.; Sevilla-Garcia, I.; Villabona-Artero, C.; Beguiristain-Gomez, A.; Llanos-Munoz, M.; et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE). Ann. Oncol. 2010, 21, 1794–1803. [Google Scholar] [CrossRef]
- Janson, E.T.; Holmberg, L.; Stridsberg, M.; Eriksson, B.; Theodorsson, E.; Wilander, E.; Oberg, K. Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann. Oncol. 1997, 8, 685–690. [Google Scholar] [CrossRef]
- Riihimaki, M.; Hemminki, A.; Sundquist, K.; Sundquist, J.; Hemminki, K. The epidemiology of metastases in neuroendocrine tumors. Int. J. Cancer 2016, 139, 2679–2686. [Google Scholar] [CrossRef]
- Scharf, M.; Petry, V.; Daniel, H.; Rinke, A.; Gress, T.M. Bone Metastases in Patients with Neuroendocrine Neoplasm: Frequency and Clinical, Therapeutic, and Prognostic Relevance. Neuroendocrinology 2018, 106, 30–37. [Google Scholar] [CrossRef]
- Kavecansky, J.; Wei, L.; Caronia, L.; Ramirez, M.T.; Bloomston, M.; Shah, M.H. Bone metastases in well-to-moderately differentiated neuroendocrine tumors: A single institutional review from the Ohio State University Medical Center. Pancreas 2015, 44, 198–203. [Google Scholar] [CrossRef] [PubMed]
- Van Loon, K.; Zhang, L.; Keiser, J.; Carrasco, C.; Glass, K.; Ramirez, M.T.; Bobiak, S.; Nakakura, E.K.; Venook, A.P.; Shah, M.H.; et al. Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr. Connect. 2015, 4, 9–17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Meijer, W.G.; van der Veer, E.; Jager, P.L.; van der Jagt, E.J.; Piers, B.A.; Kema, I.P.; de Vries, E.G.; Willemse, P.H. Bone metastases in carcinoid tumors: Clinical features, imaging characteristics, and markers of bone metabolism. J. Nucl. Med. 2003, 44, 184–191. [Google Scholar] [PubMed]
- Peri, M.; Botteri, E.; Pisa, E.; De Marinis, F.; Ungaro, A.; Spada, F.; Grana, C.M.; Gasparri, R.; Spaggiari, L.; Romentz, N.; et al. A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors. J. Thorac. Dis. 2018, 10, 3928–3939. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ross, E.M.; Roberts, W.C. The carcinoid syndrome: Comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am. J. Med. 1985, 79, 339–354. [Google Scholar] [CrossRef]
- Lombard-Bohas, C.; Mitry, E.; O’Toole, D.; Louvet, C.; Pillon, D.; Cadiot, G.; Borson-Chazot, F.; Aparicio, T.; Ducreux, M.; Lecomte, T.; et al. Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology 2009, 89, 217–222. [Google Scholar] [CrossRef] [PubMed]
- Robelin, P.; Hadoux, J.; Forestier, J.; Planchard, D.; Hervieu, V.; Berdelou, A.; Scoazec, J.Y.; Valette, P.J.; Leboulleux, S.; Ducreux, M.; et al. Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors. J. Thorac. Oncol. 2019, 14, 993–1002. [Google Scholar] [CrossRef] [PubMed]
- Alexandraki, K.I.; Pizanias, M.; Uri, I.; Thomas, D.; Page, T.; Kolomodi, D.; Low, C.S.; Adesanya, O.; Tsoli, M.; Gross, D.J.; et al. The prognosis and management of neuroendocrine neoplasms-related metastatic bone disease: Lessons from clinical practice. Endocrine 2019, 64, 690–701. [Google Scholar] [CrossRef]
- Coleman, R.E.; Gregory, W.; Marshall, H.; Wilson, C.; Holen, I. The metastatic microenvironment of breast cancer: Clinical implications. Breast 2013, 22, S50–S56. [Google Scholar] [CrossRef]
- Kaplan, R.N.; Rafii, S.; Lyden, D. Preparing the “soil”: The premetastatic niche. Cancer Res. 2006, 66, 11089–11093. [Google Scholar] [CrossRef]
- Puisieux, A.; Brabletz, T.; Caramel, J. Oncogenic roles of EMT-inducing transcription factors. Nat. Cell Biol. 2014, 16, 488–494. [Google Scholar] [CrossRef] [PubMed]
- Van der Pluijm, G. Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone 2011, 48, 37–43. [Google Scholar] [CrossRef] [PubMed]
- Brabletz, T. To differentiate or not-routes towards metastasis. Nat. Rev. Cancer 2012, 12, 425–436. [Google Scholar] [CrossRef] [PubMed]
- Sosa, M.S.; Bragado, P.; Aguirre-Ghiso, J.A. Mechanisms of disseminated cancer cell dormancy: An awakening field. Nat. Rev. Cancer 2014, 14, 611–622. [Google Scholar] [CrossRef] [PubMed]
- Shupp, A.B.; Kolb, A.D.; Mukhopadhyay, D.; Bussard, K.M. Cancer Metastases to Bone: Concepts, Mechanisms, and Interactions with Bone Osteoblasts. Cancers 2018, 10, 182. [Google Scholar] [CrossRef]
- Mundy, G.R. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2002, 2, 584–593. [Google Scholar] [CrossRef] [PubMed]
- Kingsley, L.A.; Fournier, P.G.; Chirgwin, J.M.; Guise, T.A. Molecular biology of bone metastasis. Mol. Cancer Ther. 2007, 6, 2609–2617. [Google Scholar] [CrossRef]
- Dougall, W.C. Molecular pathways: Osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin. Cancer Res. 2012, 18, 326–335. [Google Scholar] [CrossRef]
- Milone, F.; Pivonello, C.; Cariati, F.; Sarnataro, M.; Ramundo, V.; Marotta, V.; Jann, H.; Pape, U.F.; Wiedenmann, B.; Colao, A.; et al. Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases. Biomarkers 2013, 18, 121–125. [Google Scholar] [CrossRef]
- Dunn, L.K.; Mohammad, K.S.; Fournier, P.G.; McKenna, C.R.; Davis, H.W.; Niewolna, M.; Peng, X.H.; Chirgwin, J.M.; Guise, T.A. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS ONE 2009, 4, e6896. [Google Scholar] [CrossRef]
- Owen, K.L.; Parker, B.S. Beyond the vicious cycle: The role of innate osteoimmunity, automimicry and tumor-inherent changes in dictating bone metastasis. Mol. Immunol. 2019, 110, 57–68. [Google Scholar] [CrossRef] [PubMed]
- Morgan, H.; Tumber, A.; Hill, P.A. Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte/macrophage colony-stimulating factor. Int. J. Cancer 2004, 109, 653–660. [Google Scholar] [CrossRef] [PubMed]
- Chu, G.C.; Chung, L.W. RANK-mediated signaling network and cancer metastasis. Cancer Metastasis Rev. 2014, 33, 497–509. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sousa, S.; Clezardin, P. Bone-Targeted Therapies in Cancer-Induced Bone Disease. Calcif. Tissue Int. 2018, 102, 227–250. [Google Scholar] [CrossRef]
- Bendre, M.S.; Margulies, A.G.; Walser, B.; Akel, N.S.; Bhattacharrya, S.; Skinner, R.A.; Swain, F.; Ramani, V.; Mohammad, K.S.; Wessner, L.L.; et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res. 2005, 65, 11001–11009. [Google Scholar] [CrossRef]
- Podgorski, I. Future of anticathepsin K drugs: Dual therapy for skeletal disease and atherosclerosis? Future Med. Chem. 2009, 1, 21–34. [Google Scholar] [CrossRef]
- Jensen, A.B.; Wynne, C.; Ramirez, G.; He, W.; Song, Y.; Berd, Y.; Wang, H.; Mehta, A.; Lombardi, A. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: Results of a 4-week, double-blind, randomized, controlled trial. Clin. Breast Cancer 2010, 10, 452–458. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Loberg, R.; Taichman, R.S. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev. 2006, 25, 573–587. [Google Scholar] [CrossRef]
- Circelli, L.; Sciammarella, C.; Guadagno, E.; Tafuto, S.; del Basso de Caro, M.; Botti, G.; Pezzullo, L.; Aria, M.; Ramundo, V.; Tatangelo, F.; et al. CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR. Oncotarget 2016, 7, 18865–18875. [Google Scholar] [CrossRef] [Green Version]
- Cives, M.; Quaresmini, D.; Rizzo, F.M.; Felici, C.; D’Oronzo, S.; Simone, V.; Silvestris, F. Osteotropism of neuroendocrine tumors: Role of the CXCL12/ CXCR4 pathway in promoting EMT in vitro. Oncotarget 2017, 8, 22534–22549. [Google Scholar] [CrossRef]
- Cives, M.; Rizzo, F.; Simone, V.; Bisceglia, F.; Stucci, S.; Seeber, A.; Spizzo, G.; Montrone, T.; Resta, L.; Silvestris, F. Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition. Neuroendocrinology 2016, 103, 321–334. [Google Scholar] [CrossRef] [PubMed]
- Rizzo, F.M.; Vesely, C.; Childs, A.; Marafioti, T.; Khan, M.S.; Mandair, D.; Cives, M.; Ensell, L.; Lowe, H.; Akarca, A.U.; et al. Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours. Br. J. Cancer 2019, 120, 294–300. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fendrich, V.; Maschuw, K.; Waldmann, J.; Buchholz, M.; Rehm, J.; Gress, T.M.; Bartsch, D.K.; Konig, A. Epithelial-mesenchymal transition is a critical step in tumorgenesis of pancreatic neuroendocrine tumors. Cancers 2012, 4, 281–294. [Google Scholar] [CrossRef] [PubMed]
- Fendrich, V.; Waldmann, J.; Esni, F.; Ramaswamy, A.; Mullendore, M.; Buchholz, M.; Maitra, A.; Feldmann, G. Snail and Sonic Hedgehog activation in neuroendocrine tumors of the ileum. Endocr. Relat. Cancer 2007, 14, 865–874. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Galvan, J.A.; Astudillo, A.; Vallina, A.; Fonseca, P.J.; Gomez-Izquierdo, L.; Garcia-Carbonero, R.; Gonzalez, M.V. Epithelial-mesenchymal transition markers in the differential diagnosis of gastroenteropancreatic neuroendocrine tumors. Am. J. Clin. Pathol. 2013, 140, 61–72. [Google Scholar] [CrossRef] [PubMed]
- Galvan, J.A.; Astudillo, A.; Vallina, A.; Crespo, G.; Folgueras, M.V.; Gonzalez, M.V. Prognostic and diagnostic value of epithelial to mesenchymal transition markers in pulmonary neuroendocrine tumors. BMC Cancer 2014, 14, 855. [Google Scholar] [CrossRef] [PubMed]
- Gravina, G.L.; Mancini, A.; Muzi, P.; Ventura, L.; Biordi, L.; Ricevuto, E.; Pompili, S.; Mattei, C.; Di Cesare, E.; Jannini, E.A.; et al. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models. Prostate 2015, 75, 1227–1246. [Google Scholar] [CrossRef]
- Richert, M.M.; Vaidya, K.S.; Mills, C.N.; Wong, D.; Korz, W.; Hurst, D.R.; Welch, D.R. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol. Rep. 2009, 21, 761–767. [Google Scholar]
- Sun, Y.X.; Schneider, A.; Jung, Y.; Wang, J.; Dai, J.; Wang, J.; Cook, K.; Osman, N.I.; Koh-Paige, A.J.; Shim, H.; et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J. Bone Miner. Res. 2005, 20, 318–329. [Google Scholar] [CrossRef]
- Shiozawa, Y.; Pedersen, E.A.; Havens, A.M.; Jung, Y.; Mishra, A.; Joseph, J.; Kim, J.K.; Patel, L.R.; Ying, C.; Ziegler, A.M.; et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 2011, 121, 1298–1312. [Google Scholar] [CrossRef] [Green Version]
- Cheung, D.G.; Buzzetti, M.; Di Leva, G. miRNAs in bone metastasis. Expert Rev. Endocrinol. Metab. 2017, 12, 451–461. [Google Scholar] [CrossRef]
- Browne, G.; Taipaleenmaki, H.; Stein, G.S.; Stein, J.L.; Lian, J.B. MicroRNAs in the control of metastatic bone disease. Trends Endocrinol. Metab. 2014, 25, 320–327. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zatelli, M.C.; Grossrubatscher, E.M.; Guadagno, E.; Sciammarella, C.; Faggiano, A.; Colao, A. Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms. Endocr. Relat. Cancer 2017, 24, R223–R237. [Google Scholar] [CrossRef] [PubMed]
- Lee, H.W.; Lee, E.H.; Ha, S.Y.; Lee, C.H.; Chang, H.K.; Chang, S.; Kwon, K.Y.; Hwang, I.S.; Roh, M.S.; Seo, J.W. Altered expression of microRNA miR-21, miR-155, and let-7a and their roles in pulmonary neuroendocrine tumors. Pathol. Int. 2012, 62, 583–591. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Roldo, C.; Missiaglia, E.; Hagan, J.P.; Falconi, M.; Capelli, P.; Bersani, S.; Calin, G.A.; Volinia, S.; Liu, C.G.; Scarpa, A.; et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol. 2006, 24, 4677–4684. [Google Scholar] [CrossRef] [PubMed]
- Zoni, E.; van der Pluijm, G. The role of microRNAs in bone metastasis. J. Bone Oncol. 2016, 5, 104–108. [Google Scholar] [CrossRef] [PubMed]
- Johansson, J.; Berg, T.; Kurzejamska, E.; Pang, M.F.; Tabor, V.; Jansson, M.; Roswall, P.; Pietras, K.; Sund, M.; Religa, P.; et al. MiR-155-mediated loss of C/EBPbeta shifts the TGF-beta response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene 2013, 32, 5614–5624. [Google Scholar] [CrossRef]
- Thorns, C.; Schurmann, C.; Gebauer, N.; Wallaschofski, H.; Kumpers, C.; Bernard, V.; Feller, A.C.; Keck, T.; Habermann, J.K.; Begum, N.; et al. Global microRNA profiling of pancreatic neuroendocrine neoplasias. Anticancer Res. 2014, 34, 2249–2254. [Google Scholar]
- Liu, X.D.; Cai, F.; Liu, L.; Zhang, Y.; Yang, A.L. MicroRNA-210 is involved in the regulation of postmenopausal osteoporosis through promotion of VEGF expression and osteoblast differentiation. Biol. Chem. 2015, 396, 339–347. [Google Scholar] [CrossRef]
- Kimura, T. Multidisciplinary Approach for Bone Metastasis: A Review. Cancers 2018, 10, 156. [Google Scholar] [CrossRef]
- Coleman, R.E. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 2001, 27, 165–176. [Google Scholar] [CrossRef] [PubMed]
- Ulas, A.; Bilici, A.; Durnali, A.; Tokluoglu, S.; Akinci, S.; Silay, K.; Oksuzoglu, B.; Alkis, N. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases. Tumor Biol. 2016, 37, 1131–1140. [Google Scholar] [CrossRef] [PubMed]
- Guan, M.; He, I.; Luu, M.; David, J.; Gong, J.; Placencio-Hickok, V.R.; Reznik, R.S.; Tuli, R.; Hendifar, A.E. Palliative Radiation Therapy for Bone Metastases in Neuroendocrine Neoplasms. Adv. Radiat. Oncol. 2019, 4, 513–519. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- D’Oronzo, S.; Coleman, R.; Brown, J.; Silvestris, F. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management. J. Bone Oncol. 2019, 15, 004. [Google Scholar] [CrossRef] [PubMed]
- Di Martino, A.; Caldaria, A.; De Vivo, V.; Denaro, V. Metastatic epidural spinal cord compression. Expert Rev. Anticancer Ther. 2016, 16, 1189–1198. [Google Scholar] [CrossRef] [PubMed]
- Prasad, D.; Schiff, D. Malignant spinal-cord compression. Lancet Oncol. 2005, 6, 15–24. [Google Scholar] [CrossRef]
- Gray, J.A.; Nishikawa, H.; Jamous, M.A.; Grahame-Smith, D.G. Spinal cord compression due to carcinoid metastasis. Postgrad. Med. J. 1988, 64, 703–705. [Google Scholar] [CrossRef] [PubMed]
- Shi, W.; Johnston, C.F.; Buchanan, K.D.; Ferguson, W.R.; Laird, J.D.; Crothers, J.G.; McIlrath, E.M. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): A comparative study with CT and MR imaging. QJM 1998, 91, 295–301. [Google Scholar] [CrossRef] [PubMed]
- Stecco, A.; Trisoglio, A.; Soligo, E.; Berardo, S.; Sukhovei, L.; Carriero, A. Whole-Body MRI with Diffusion-Weighted Imaging in Bone Metastases: A Narrative Review. Diagnostics 2018, 8, 45. [Google Scholar] [CrossRef] [PubMed]
- Carlbom, L.; Caballero-Corbalan, J.; Granberg, D.; Sorensen, J.; Eriksson, B.; Ahlstrom, H. Whole-body MRI including diffusion-weighted MRI compared with 5-HTP PET/CT in the detection of neuroendocrine tumors. Upsala J. Med. Sci 2017, 122, 43–50. [Google Scholar] [CrossRef] [PubMed]
- Zuetenhorst, J.M.; Hoefnageli, C.A.; Boot, H.; Valdes Olmos, R.A.; Taal, B.G. Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl. Med. Commun. 2002, 23, 735–741. [Google Scholar] [CrossRef] [PubMed]
- Lebtahi, R.; Cadiot, G.; Delahaye, N.; Genin, R.; Daou, D.; Peker, M.C.; Chosidow, D.; Faraggi, M.; Mignon, M.; Le Guludec, D. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: Bone scintigraphy compared with somatostatin receptor scintigraphy. J. Nucl. Med. 1999, 40, 1602–1608. [Google Scholar] [PubMed]
- Putzer, D.; Gabriel, M.; Henninger, B.; Kendler, D.; Uprimny, C.; Dobrozemsky, G.; Decristoforo, C.; Bale, R.J.; Jaschke, W.; Virgolini, I.J. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J. Nucl. Med. 2009, 50, 1214–1221. [Google Scholar] [CrossRef] [PubMed]
- Gabriel, M.; Decristoforo, C.; Kendler, D.; Dobrozemsky, G.; Heute, D.; Uprimny, C.; Kovacs, P.; Von Guggenberg, E.; Bale, R.; Virgolini, I.J. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J. Nucl. Med. 2007, 48, 508–518. [Google Scholar] [CrossRef]
- Buchmann, I.; Henze, M.; Engelbrecht, S.; Eisenhut, M.; Runz, A.; Schafer, M.; Schilling, T.; Haufe, S.; Herrmann, T.; Haberkorn, U. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 1617–1626. [Google Scholar] [CrossRef]
- Etchebehere, E.C.; de Oliveira Santos, A.; Gumz, B.; Vicente, A.; Hoff, P.G.; Corradi, G.; Ichiki, W.A.; de Almeida Filho, J.G.; Cantoni, S.; Camargo, E.E.; et al. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: A prospective trial. J. Nucl. Med. 2014, 55, 1598–1604. [Google Scholar] [CrossRef] [PubMed]
- Antunes, P.; Ginj, M.; Zhang, H.; Waser, B.; Baum, R.P.; Reubi, J.C.; Maecke, H. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 982–993. [Google Scholar] [CrossRef]
- Gauthe, M.; Testart Dardel, N.; Ruiz Santiago, F.; Ohnona, J.; Nataf, V.; Montravers, F.; Talbot, J.N. Vertebral metastases from neuroendocrine tumours: How to avoid false positives on (68)Ga-DOTA-TOC PET using CT pattern analysis? Eur. Radiol. 2018, 28, 3943–3952. [Google Scholar] [CrossRef]
- Albanus, D.R.; Apitzsch, J.; Erdem, Z.; Erdem, O.; Verburg, F.A.; Behrendt, F.F.; Mottaghy, F.M.; Heinzel, A. Clinical value of (6)(8)Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET). Eur. J. Radiol. 2015, 84, 1866–1872. [Google Scholar] [CrossRef]
- Ambrosini, V.; Nanni, C.; Zompatori, M.; Campana, D.; Tomassetti, P.; Castellucci, P.; Allegri, V.; Rubello, D.; Montini, G.; Franchi, R.; et al. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 722–727. [Google Scholar] [CrossRef]
- Ambrosini, V.; Fanti, S. 68Ga-DOTA-peptides in the diagnosis of NET. PET Clin. 2014, 9, 37–42. [Google Scholar] [CrossRef] [PubMed]
- Panagiotidis, E.; Alshammari, A.; Michopoulou, S.; Skoura, E.; Naik, K.; Maragkoudakis, E.; Mohmaduvesh, M.; Al-Harbi, M.; Belda, M.; Caplin, M.E.; et al. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors. J. Nucl. Med. 2017, 58, 91–96. [Google Scholar] [CrossRef] [PubMed]
- Becherer, A.; Szabo, M.; Karanikas, G.; Wunderbaldinger, P.; Angelberger, P.; Raderer, M.; Kurtaran, A.; Dudczak, R.; Kletter, K. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J. Nucl. Med. 2004, 45, 1161–1167. [Google Scholar] [PubMed]
- Skoura, E.; Michopoulou, S.; Mohmaduvesh, M.; Panagiotidis, E.; Al Harbi, M.; Toumpanakis, C.; Almukhailed, O.; Kayani, I.; Syed, R.; Navalkissoor, S.; et al. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom. J. Nucl. Med. 2016, 57, 34–40. [Google Scholar] [CrossRef] [PubMed]
- Herrmann, K.; Czernin, J.; Wolin, E.M.; Gupta, P.; Barrio, M.; Gutierrez, A.; Schiepers, C.; Mosessian, S.; Phelps, M.E.; Allen-Auerbach, M.S. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: The referring physician’s perspective. J. Nucl. Med. 2015, 56, 70–75. [Google Scholar] [CrossRef] [PubMed]
- D’Oronzo, S.; Brown, J.; Coleman, R. The value of biomarkers in bone metastasis. Eur. J. Cancer Care (Engl.) 2017, 26, e12725. [Google Scholar] [CrossRef] [PubMed]
- Strosberg, J.; Gardner, N.; Kvols, L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 2009, 89, 471–476. [Google Scholar] [CrossRef]
- Carmona-Bayonas, A.; Jimenez-Fonseca, P.; Lamarca, A.; Barriuso, J.; Castano, A.; Benavent, M.; Alonso, V.; Riesco-Martinez, M.D.C.; Alonso-Gordoa, T.; Custodio, A.; et al. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. J. Clin. Oncol. 2019. [Google Scholar] [CrossRef]
- Farooki, A. NCCN bone health task force: Key recommendations. J. Natl. Compr. Cancer Netw. 2014, 12, 813–816. [Google Scholar] [CrossRef]
- Saad, F.; Lipton, A.; Cook, R.; Chen, Y.M.; Smith, M.; Coleman, R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110, 1860–1867. [Google Scholar] [CrossRef]
- Ayala-Ramirez, M.; Palmer, J.L.; Hofmann, M.C.; de la Cruz, M.; Moon, B.S.; Waguespack, S.G.; Habra, M.A.; Jimenez, C. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J. Clin. Endocrinol. Metab. 2013, 98, 1492–1497. [Google Scholar] [CrossRef] [PubMed]
- Thacker, P.G.; Callstrom, M.R.; Curry, T.B.; Mandrekar, J.N.; Atwell, T.D.; Goetz, M.P.; Rubin, J. Palliation of painful metastatic disease involving bone with imaging-guided treatment: Comparison of patients’ immediate response to radiofrequency ablation and cryoablation. AJR Am. J. Roentgenol. 2011, 197, 510–515. [Google Scholar] [CrossRef] [PubMed]
- Deschamps, F.; Farouil, G.; Ternes, N.; Gaudin, A.; Hakime, A.; Tselikas, L.; Teriitehau, C.; Baudin, E.; Auperin, A.; de Baere, T. Thermal ablation techniques: A curative treatment of bone metastases in selected patients? Eur. Radiol. 2014, 24, 1971–1980. [Google Scholar] [CrossRef]
- Himelstein, A.L.; Foster, J.C.; Khatcheressian, J.L.; Roberts, J.D.; Seisler, D.K.; Novotny, P.J.; Qin, R.; Go, R.S.; Grubbs, S.S.; O’Connor, T.; et al. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 2017, 317, 48–58. [Google Scholar] [CrossRef] [PubMed]
- Henry, D.H.; Costa, L.; Goldwasser, F.; Hirsh, V.; Hungria, V.; Prausova, J.; Scagliotti, G.V.; Sleeboom, H.; Spencer, A.; Vadhan-Raj, S.; et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 2011, 29, 1125–1132. [Google Scholar] [CrossRef] [PubMed]
- Lipton, A.; Fizazi, K.; Stopeck, A.T.; Henry, D.H.; Smith, M.R.; Shore, N.; Martin, M.; Vadhan-Raj, S.; Brown, J.E.; Richardson, G.E.; et al. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. Eur. J. Cancer 2016, 53, 75–83. [Google Scholar] [CrossRef] [PubMed]
- Body, J.J.; Bone, H.G.; de Boer, R.H.; Stopeck, A.; Van Poznak, C.; Damiao, R.; Fizazi, K.; Henry, D.H.; Ibrahim, T.; Lipton, A.; et al. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur. J. Cancer 2015, 51, 1812–1821. [Google Scholar] [CrossRef] [PubMed]
- Coleman, R.; Body, J.J.; Aapro, M.; Hadji, P.; Herrstedt, J.; Group, E.G.W. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann. Oncol. 2014, 25 (Suppl S3), iii124–iii137. [Google Scholar] [CrossRef]
- O’Sullivan, J.M.; Carles, J.; Cathomas, R.; Gomez-Iturriaga, A.; Heinrich, D.; Kramer, G.; Ost, P.; van Oort, I.; Tombal, B. Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group. Eur. Urol. Oncol. 2019. [Google Scholar] [CrossRef] [PubMed]
- Heinrich, D.; Bektic, J.; Bergman, A.M.; Caffo, O.; Cathomas, R.; Chi, K.N.; Daugaard, G.; Keizman, D.; Kindblom, J.; Kramer, G.; et al. The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. Clin. Genitourin. Cancer 2017, 16, e223–e231. [Google Scholar] [CrossRef] [Green Version]
- Henriksen, G.; Breistol, K.; Bruland, O.S.; Fodstad, O.; Larsen, R.H. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 2002, 62, 3120–3125. [Google Scholar] [PubMed]
- Geva, R.; Lopez, J.; Danson, S.; Joensuu, H.; Peer, A.; Harris, S.J.; Souza, F.; Pereira, K.M.C.; Perets, R. Radium-223 in combination with paclitaxel in cancer patients with bone metastases: Safety results from an open-label, multicenter phase Ib study. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 1092–1101. [Google Scholar] [CrossRef] [PubMed]
- Pavel, M.; O’Toole, D.; Costa, F.; Capdevila, J.; Gross, D.; Kianmanesh, R.; Krenning, E.; Knigge, U.; Salazar, R.; Pape, U.F.; et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology 2016, 103, 172–185. [Google Scholar] [CrossRef] [PubMed]
- Pavel, M.; Valle, J.W.; Eriksson, B.; Rinke, A.; Caplin, M.; Chen, J.; Costa, F.; Falkerby, J.; Fazio, N.; Gorbounova, V.; et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy—Biotherapy and Novel Targeted Agents. Neuroendocrinology 2017, 105, 266–280. [Google Scholar] [CrossRef] [PubMed]
- Kwekkeboom, D.J.; de Herder, W.W.; Kam, B.L.; van Eijck, C.H.; van Essen, M.; Kooij, P.P.; Feelders, R.A.; van Aken, M.O.; Krenning, E.P. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival. J. Clin. Oncol. 2008, 26, 2124–2130. [Google Scholar] [CrossRef] [PubMed]
- Sabet, A.; Khalaf, F.; Haslerud, T.; Al-Zreiqat, A.; Sabet, A.; Simon, B.; Poppel, T.D.; Biersack, H.J.; Ezziddin, S. Bone metastases in GEP-NET: Response and long-term outcome after PRRT from a follow-up analysis. Am. J. Nucl. Med. Mol. Imaging 2013, 3, 437–445. [Google Scholar] [PubMed]
- Ezziddin, S.; Sabet, A.; Heinemann, F.; Yong-Hing, C.J.; Ahmadzadehfar, H.; Guhlke, S.; Holler, T.; Willinek, W.; Boy, C.; Biersack, H.J. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. J. Nucl. Med. 2011, 52, 1197–1203. [Google Scholar] [CrossRef] [PubMed]
- Hicks, R.J.; Kwekkeboom, D.J.; Krenning, E.; Bodei, L.; Grozinsky-Glasberg, S.; Arnold, R.; Borbath, I.; Cwikla, J.; Toumpanakis, C.; Kaltsas, G.; et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology 2017, 105, 295–309. [Google Scholar] [CrossRef]
- Garcia-Carbonero, R.; Rinke, A.; Valle, J.W.; Fazio, N.; Caplin, M.; Gorbounova, V.; O’Connor, J.; Eriksson, B.; Sorbye, H.; Kulke, M.; et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy. Neuroendocrinology 2017, 105, 281–294. [Google Scholar] [CrossRef]
- Browne, A.J.; Kubasch, M.L.; Gobel, A.; Hadji, P.; Chen, D.; Rauner, M.; Stolzel, F.; Hofbauer, L.C.; Rachner, T.D. Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer. Breast Cancer Res. 2017, 19, 92. [Google Scholar] [CrossRef]
- Escudier, B.; Powles, T.; Motzer, R.J.; Olencki, T.; Aren Frontera, O.; Oudard, S.; Rolland, F.; Tomczak, P.; Castellano, D.; Appleman, L.J.; et al. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. J. Clin. Oncol. 2018, 36, 765–772. [Google Scholar] [CrossRef] [PubMed]
- Cives, M.; Pelle, E.; Quaresmini, D.; Rizzo, F.M.; Tucci, M.; Silvestris, F. The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications. Neuroendocrinology 2019. [Google Scholar] [CrossRef] [PubMed]
ID | STATUS 1 | PHASE | STUDY TITLE | INTERVENTION | PRIMARY OUTCOME |
---|---|---|---|---|---|
NCT03986593 | Recruiting | Not Applicable | Cryoablation of Bone Metastases from Endocrine Tumors | Cryoablation | Change in the local disease status of the cryoablation-treated bone metastases; absence of neurological impairment and/or pain. |
NCT02743741 | Recruiting | Not Applicable | Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor PositiveNeuroendocrine Tumors | Lutetium-177 Octreotate | The proportion of patients who are progression-free using RECIST 1.1 criteria [Time frame: up to 12 months]. |
NCT02489604 | Recruiting | 2 | Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors | 177Lu-DOTATATE 25.9 GBq activity; 177Lu-DOTATATE 18.5 GBq activity | Disease control rate (DCR) [Time frame: up to 7 years]. |
NCT03478358 | Recruiting | 1 | Treatment Using 177Lu-DOTA-EB-TATE in Patients with Advanced Neuroendocrine Tumors | 177Lu-DOTA-EB-TATE 1; 177Lu-DOTA-TATE; 177Lu-DOTA-EB-TATE 2; 177Lu-DOTA-EB-TATE 3. | Change of standardized uptake value of 68Ga-DOTA-TATE before and after treatment in metastatic neuroendocrine tumors [Time frame: 1 year]. |
NCT00004074 | Completed | 1 | Interleukin-12 and Trastuzumab in Treating Patients with Cancer That Has High Levels of HER2/Neu | Recombinant interleukin-12; ABI007/carboplatin/trastuzumab | Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs), graded using the CTCAE v2.0 criteria. |
NCT00005842 | Completed | 1 | Trastuzumab Plus R115777 in Treating Patients with Advanced or Metastatic Cancer | Trastuzumab; tipifarnib | Determine the maximum tolerated dose of R115777 when administered with trastuzumab (Herceptin). |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Altieri, B.; Di Dato, C.; Martini, C.; Sciammarella, C.; Di Sarno, A.; Colao, A.; Faggiano, A., on behalf of NIKE Group. Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management. Cancers 2019, 11, 1332. https://doi.org/10.3390/cancers11091332
Altieri B, Di Dato C, Martini C, Sciammarella C, Di Sarno A, Colao A, Faggiano A on behalf of NIKE Group. Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management. Cancers. 2019; 11(9):1332. https://doi.org/10.3390/cancers11091332
Chicago/Turabian StyleAltieri, Barbara, Carla Di Dato, Chiara Martini, Concetta Sciammarella, Antonella Di Sarno, Annamaria Colao, and Antongiulio Faggiano on behalf of NIKE Group. 2019. "Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management" Cancers 11, no. 9: 1332. https://doi.org/10.3390/cancers11091332